Yes, provided there are no inconsistencies. The texts for the outer packaging, primary packaging and, if applicable, package leaflet and SmPC may not contain any textual deviations from the labelling, if applicable, package leaflet and SmPC of the medicinal product authorised or registered in Austria, apart from company-specific information and information to avoid inconsistencies.
Yes, the 'repackaging' of blisters in the context of repackaging is permitted under Community case-law. From the perspective of counterfeit medicines, however, we would like to point out that any perceptible manipulation may give rise to suspicion of counterfeiting, since it is not immediately apparent whether the manipulation took place in the context of authorised manufacture or in an unfair context.
Information on the security features according to Directive 2011/62/EU can be found on the homepage of the European Commission, in particular the continuously updated and extended 'Questions and Answers' document on the Delegate Regulation 2016/161/EU. The Implementation plan of the EMA and the CMDh can also be found there. For general enquiries on the subject of "Serialisation and national implementation", the e-mail address email@example.com has been set up.
See also § 10c (5) AMG. From the point of view of the BASG, this provision must be interpreted as meaning that the marketing authorisation holder must be informed at the latest at the same time as the application; from the point of view of the BASG, there is nothing to prevent an earlier communication, provided that it contains exactly the same information as the later application for approval.